236 related articles for article (PubMed ID: 24574120)
21. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
Yu W; Tang L; Lin F; Yao Y; Shen Z
Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant Chemotherapy Followed by Delayed Surgery: Is it Necessary for All Patients With Nonmetastatic High-Grade Pelvic Osteosarcoma?
Xu J; Xie L; Guo W
Clin Orthop Relat Res; 2018 Nov; 476(11):2177-2186. PubMed ID: 29912746
[TBL] [Abstract][Full Text] [Related]
23. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
[TBL] [Abstract][Full Text] [Related]
24. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.
Nataraj V; Rastogi S; Khan SA; Sharma MC; Agarwala S; Vishnubhatla S; Bakhshi S
Clin Transl Oncol; 2016 Sep; 18(9):937-44. PubMed ID: 26742936
[TBL] [Abstract][Full Text] [Related]
25. Should High-grade Extraosseous Osteosarcoma Be Treated With Multimodality Therapy Like Other Soft Tissue Sarcomas?
Fan Z; Patel S; Lewis VO; Guadagnolo BA; Lin PP
Clin Orthop Relat Res; 2015 Nov; 473(11):3604-11. PubMed ID: 26197952
[TBL] [Abstract][Full Text] [Related]
26. Tumor necrosis rate adjusted by tumor volume change is a better predictor of survival of localized osteosarcoma patients.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Jeon DG
Ann Surg Oncol; 2008 Mar; 15(3):906-14. PubMed ID: 18163171
[TBL] [Abstract][Full Text] [Related]
27. Modeling Continuous Prognostic Factors in Survival Analysis: Implications for Tumor Staging and Assessing Chemotherapy Effect in Osteosarcoma.
Cates JMM
Am J Surg Pathol; 2018 Apr; 42(4):485-491. PubMed ID: 29200101
[TBL] [Abstract][Full Text] [Related]
28. What are the factors that affect survival and relapse after local recurrence of osteosarcoma?
Takeuchi A; Lewis VO; Satcher RL; Moon BS; Lin PP
Clin Orthop Relat Res; 2014 Oct; 472(10):3188-95. PubMed ID: 24980644
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors in the survival of patients diagnosed with primary non-metastatic osteosarcoma with a poor response to neoadjuvant chemotherapy.
Bispo Júnior RZ; Camargo OP
Clinics (Sao Paulo); 2009; 64(12):1177-86. PubMed ID: 20037705
[TBL] [Abstract][Full Text] [Related]
30. Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J.
Iwamoto Y; Tanaka K; Isu K; Kawai A; Tatezaki S; Ishii T; Kushida K; Beppu Y; Usui M; Tateishi A; Furuse K; Minamizaki T; Kawaguchi N; Yamawaki S
J Orthop Sci; 2009 Jul; 14(4):397-404. PubMed ID: 19662473
[TBL] [Abstract][Full Text] [Related]
31. Vitronectin significantly influences prognosis in osteosarcoma.
Shi K; Lan RL; Tao X; Wu CY; Hong HF; Lin JH
Int J Clin Exp Pathol; 2015; 8(9):11364-71. PubMed ID: 26617861
[TBL] [Abstract][Full Text] [Related]
32. Does amputation offer any survival benefit over limb salvage in osteosarcoma patients with poor chemonecrosis and close margins?
Reddy KI; Wafa H; Gaston CL; Grimer RJ; Abudu AT; Jeys LM; Carter SR; Tillman RM
Bone Joint J; 2015 Jan; 97-B(1):115-20. PubMed ID: 25568424
[TBL] [Abstract][Full Text] [Related]
33. Does expression of glucose transporter protein-1 relate to prognosis and angiogenesis in osteosarcoma?
Kubo T; Shimose S; Fujimori J; Furuta T; Arihiro K; Ochi M
Clin Orthop Relat Res; 2015 Jan; 473(1):305-10. PubMed ID: 25193692
[TBL] [Abstract][Full Text] [Related]
34. [Prediction of chemotherapy response in primary osteosarcoma using the machine learning technique on radiomic data].
Dufau J; Bouhamama A; Leporq B; Malaureille L; Beuf O; Gouin F; Pilleul F; Marec-Berard P
Bull Cancer; 2019 Nov; 106(11):983-999. PubMed ID: 31587802
[TBL] [Abstract][Full Text] [Related]
35. Cyclooxygenase-2 overexpression predicts poor survival in patients with high-grade extremity osteosarcoma: a pilot study.
Urakawa H; Nishida Y; Naruse T; Nakashima H; Ishiguro N
Clin Orthop Relat Res; 2009 Nov; 467(11):2932-8. PubMed ID: 19326179
[TBL] [Abstract][Full Text] [Related]
36. Pre-Operative chemotherapy response assessed by contrast-enhanced MRI can predict the prognosis of Enneking surgical margins in patients with osteosarcoma.
He F; Qin L; Bao Q; Zang S; He Q; Qiu S; Shen Y; Zhang W
J Orthop Res; 2019 Jan; 37(1):258-264. PubMed ID: 30255519
[TBL] [Abstract][Full Text] [Related]
37. Surgical resection of relapse may improve postrelapse survival of patients with localized osteosarcoma.
Wong KC; Lee V; Shing MM; Kumta S
Clin Orthop Relat Res; 2013 Mar; 471(3):814-9. PubMed ID: 22972657
[TBL] [Abstract][Full Text] [Related]
38. Growth patterns of osteosarcoma predict patient survival.
Kim MS; Lee SY; Cho WH; Song WS; Koh JS; Lee JA; Yoo JY; Shin DS; Jeon DG
Arch Orthop Trauma Surg; 2009 Sep; 129(9):1189-96. PubMed ID: 18682966
[TBL] [Abstract][Full Text] [Related]
39. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
[TBL] [Abstract][Full Text] [Related]
40. MRI Identification of the Osseous Extent of Pediatric Bone Sarcomas.
Thompson MJ; Shapton JC; Punt SE; Johnson CN; Conrad EU
Clin Orthop Relat Res; 2018 Mar; 476(3):559-564. PubMed ID: 29529641
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
